← Back to Search

Cannabinoid

Cannabidiol for Schizophrenia (CBD Trial)

Phase 2
Waitlist Available
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up completed each time subject is seen over 10 weeks (screening, period 1 baseline, period 1 week 1, period 1 week 2, period 1 week 3, period 1 week 4, period 2 baseline, period 2 week 1, period 2 week 2, period 2 week 3, period 2 week 4)
Awards & highlights

CBD Trial Summary

This trial is testing whether cannabidiol (CBD) can improve symptoms and functioning in people with schizophrenia.

Eligible Conditions
  • Schizophrenia
  • Schizoaffective Disorder

CBD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~completed each time subject is seen over 10 weeks (screening, period 1 baseline, period 1 week 1, period 1 week 2, period 1 week 3, period 1 week 4, period 2 baseline, period 2 week 1, period 2 week 2, period 2 week 3, period 2 week 4)
This trial's timeline: 3 weeks for screening, Varies for treatment, and completed each time subject is seen over 10 weeks (screening, period 1 baseline, period 1 week 1, period 1 week 2, period 1 week 3, period 1 week 4, period 2 baseline, period 2 week 1, period 2 week 2, period 2 week 3, period 2 week 4) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Global Impression of Severity Scale Over Time
Positive and Negative Syndrome Scale (PANSS) Over Time
Secondary outcome measures
Patient Assessment of Own Functioning Inventory (PAOFI) Over Time
Quality of Life Scale (QLS) Over Time

CBD Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo, then CannabidiolExperimental Treatment2 Interventions
The subject will receive placebo for four weeks, followed by a two week washout period, followed by four weeks of treatment with cannabidiol (CBD)(800mg/day).
Group II: Cannabidiol, then PlaceboExperimental Treatment2 Interventions
The subject will receive treatment with cannabidiol (CBD)(800mg/day) for four weeks, followed by a two week washout period, followed by four weeks of placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol
2021
Completed Phase 3
~1010
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,510 Total Patients Enrolled
59 Trials studying Schizophrenia
4,001 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Ohio
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Cannabidiol Treatment in Patients With Early Psychosis
Mohini Ranganathan 2016. "Cannabidiol Treatment in Patients With Early Psychosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02504151.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top